(Q39011809)

English

Combining trastuzumab and cetuximab combats trastuzumab-resistant gastric cancer by effective inhibition of EGFR/ErbB2 heterodimerization and signaling

scientific article published on 26 March 2014

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Combining trastuzumab and cetuximab combats trastuzumab-resistant gastric cancer by effective inhibition of EGFR/ErbB2 heterodimerization and signaling (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

protein heterodimerization activity

1 reference

based on heuristic

inferred from title

author name string

Lei Zheng

1

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Wenlong Tan

2

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Jinrong Zhang

3

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Dongcai Yuan

4

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Jingci Yang

5

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Hongmei Liu

6

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

publication date

26 March 2014

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

63

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

581-586

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1541-Z

21 January 2018

Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1541-Z

21 January 2018

Clinical significance of insulin-like growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1541-Z

21 January 2018

Trastuzumab--mechanism of action and use in clinical practice

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1541-Z

21 January 2018

HER2 therapy: molecular mechanisms of trastuzumab resistance.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1541-Z

21 January 2018

Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1541-Z

21 January 2018

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1541-Z

21 January 2018

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1541-Z

21 January 2018

Interaction of antibodies with ErbB receptor extracellular regions

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1541-Z

21 January 2018

In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1541-Z

21 January 2018

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1541-Z

21 January 2018

Identifiers

10.1007/S00262-014-1541-Z

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39011809&oldid=2202458864"